Psoriasis severity and the prevalence of major medical comorbidity: A population-based study

JAMA Dermatology

Volumn 149, Issue 10, 2013, Pages 1173-1179

  Yeung, Howa ^a   Takeshita, Junko ^a   Mehta, Nehal N ^b   Kimmel, Stephen E ^a   Ogdie, Alexis ^a   Margolis, David J ^a   Shin, Daniel B ^a   Attor, Rosemary ^a   Troxel, Andrea B ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PSORIASIS; RHEUMATIC DISEASE;

ADULT; BODY SURFACE AREA; CASE-CONTROL STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84885902717     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.5015     Document Type: Article

References (47)

1. Gelfand JM,Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12): 1537-1541.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2): 136-139.
3. Gelfand JM, Neimann AL, Shin DB,Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735-1741.
4. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10): 2411-2418.
5. Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012;33(16): 2054-2064.
6. Prodanovich S, Kirsner RS, Kravetz JD,Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6): 700-703.
7. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol. 2008;159(6): 1331-1337.
8. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145(4): 379-382.
9. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8): 1000-1006.
10. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3): 586-592.
11. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1): 84-91.
12. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148(9): 995-1000.
13. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5): 1037-1043.
14. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2): 147-151.
15. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3, pt 1): 556-562.
16. GulliverW. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159(suppl 2): 2-9.
17. Kimball AB, Gladman D, Gelfand JM, et al National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J AmAcad Dermatol. 2008;58(6): 1031-1042.
18. Lewis JD, Schinnar R, Bilker WB,Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4): 393-401.
19. Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol. 2011;164(3): 602-609.
20. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? results of National Psoriasis Foundation survey. J AmAcad Dermatol. 2007;57(6): 957-962.
21. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3): 280-284.
22. Dommasch ED, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol. 2010;162(4): 835-842.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5): 373-383.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11): 1130-1139.
25. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC FamPract. 2010;11: 1. doi: 10.1186/1471-2296-11-1.
26. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12): 1493-1499.
27. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24): 2525-2531.
28. Lan CC, Ko YC, Yu HS, et al.Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol. 2012;92(4): 349-352.
29. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS.Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis [published correction appears in J AmAcad Dermatol. 2005;52(4): 670]. J Am Acad Dermatol. 2005;52(2): 262-267.
30. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]- fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9): 1031-1039.
31. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions [published correction appears in J Invest Dermatol. 2010;130(10): 2517]. J Invest Dermatol. 2010;130(7): 1785-1796.
32. Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012;132(3, pt 2): 915-922.
33. Wang Y, Gao H, Loyd CM, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132(8): 2067-2075.
34. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4): 778-786.
35. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4): 758-764.
36. Kanada KN, Schupp CW, Armstrong AW. Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus [published onlineMay 7, 2012]. J Eur Acad Dermatol Venereol. doi: 10.1111/j.1468-3083.2012.04563.x.
37. Taglione E, Vatteroni ML, Martini P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol. 1999;26(2): 370-372.
38. Cohen AD,Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology. 2010;220(3): 218-222.
39. WeirMR. Microalbuminuria and cardiovascular disease. Clin J AmSoc Nephrol. 2007;2(3): 581-590.
40. Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol. 2012;44(2): 509-514.
41. Szepietowski JC, Bielicka E,Wasik F, KopecW, Szepietowski T. Microalbuminuria as a subclinical marker of renal impairment in subjects with psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2000;14(6): 513-514.
42. Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A. Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology. 1992;185(2): 93-95.
43. Madeddu P, Ena P, Glorioso N, Cerimele D, Rappelli A. High prevalence of microproteinuria, an early index of renal impairment, in patients with diffuse psoriasis. Nephron. 1988;48(3): 222-225.
44. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005;16(5-6): 319-323.
45. Dreiher J,Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4): 956-960.
46. Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2012;26(1): 59-65.
47. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J AmAcad Dermatol. 2012;67(5): 924-930.